In a recent article, Morgan and Persaud criticize Canada's drug plan managers for a recent
extension of a generic drug pricing agreement. 1 They explain that New Zealand has lower …

The article focuses on the impact of Ontario's policy on drug pricing on other Canadian
provinces. It mentions that British Columbia and Nova Scotia are negotiating to come up with …

Pfizer's attempts to keep generic versions of Lipitor (atorvastatin) at bay in the US markets
were dealt a blow recently when the US Court of Appeals ruled that one of its key patents for …

Abstract In Australian Competition and Consumer Commission v Pfizer Australia Pty Ltd
[2015] FCA 113 the ACCC alleged that Pfizer's 'Project LEAP'involved a scheme to lock …

We would like to thank Professor Philip Clarke for highlighting the issue of high cost generic
medications, identifying pricing data, and commenting on the report; the many other …

E846 CMAJ| JUNE 19, 2017| VOLUME 189| ISSUE 24 said Jim Keon, president of the
Canadian Generic Pharmaceutical Association.“Health Canada review staff would first pick …

Ontario Ministry of Health and Long-Term Care ties.(Any payment above the 20%, with
respect to the provincial drug plan, is deemed a rebate under the law.) The professional …

CMAJ| JUNE 12, 2017| VOLUME 189| ISSUE 23 E793 made a start at collective bargaining
with the pan-Canadian Pharmaceutical Alliance, but the provinces must first decide which …

The problem of obtaining fair pricing for generic drugs has led to a series of regulatory
measures in Canadian provinces. This paper offers a new way of thinking about the …

There is a widespread perception that drug prices in the US are much higher than they
should be, and that the problem is only getting worse. Critics argue that the pharmaceutical …